Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 12/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 12/20 | 0.42 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.41 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.41 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720300 | 0.89 | CYP2D6 (0.43) | MCHR1L3MBTL3L3MBTL1TP53BP1L3MBTL4 | |
| SCHEMBL1719458 | 0.86 | L3MBTL3 (0.39) | MCHR1L3MBTL3L3MBTL1MCHR2MBTD1 | |
| SCHEMBL1719200 | 0.85 | MCHR1 (0.39) | MCHR1L3MBTL3L3MBTL1MCHR2MBTD1 | |
| SCHEMBL1719996 | 0.85 | EPHX2 (0.40) | HTR2BHSD11B1KMT2A | |
| SCHEMBL1719995 | 0.85 | EPHX2 (0.40) | HTR2BHSD11B1KMT2A | |
| SCHEMBL1719366 | 0.84 | PIK3CD (0.42) | MCHR1L3MBTL3L3MBTL1MCHR2MBTD1 | |
| SCHEMBL1724292 | 0.84 | MCHR1 (0.38) | MCHR1L3MBTL3L3MBTL1MCHR2MBTD1 | |
| SCHEMBL1719441 | 0.84 | ABL1 (0.39) | MCHR1L3MBTL3L3MBTL1MCHR2HTR2B | |
| SCHEMBL1720060 | 0.84 | MCHR1 (0.39) | MCHR1L3MBTL3L3MBTL1MCHR2HTR2B | |
| SCHEMBL1719322 | 0.83 | HTR2B (0.38) | MCHR1L3MBTL3L3MBTL1MCHR2MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101687844-B | Imidazole derivatives as CCR2 receptor antagonists | HOFFMANN LA ROCHE | 2013-11-13 | — | — | CN | disclosed |
| EP-2173735-B1 | IMIDAZOLE DERIVATIVES AS CCR2 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-01-11 | — | — | EP | disclosed |
| EP-2173735-B1 | IMIDAZOLE DERIVATIVES AS CCR2 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-01-11 | — | — | EP | disclosed |
| US-7935707-B2 | Imidazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935707-B2 | Imidazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935707-B2 | Imidazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2173735-A1 | IMIDAZOLE DERIVATIVES AS CCR2 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-04-14 | — | — | EP | disclosed |
| US-20090012063-A1 | Novel imidazole derivatives | HOFFMANN-LA ROCHE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012063-A1 | Novel imidazole derivatives | HOFFMANN-LA ROCHE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012063-A1 | Novel imidazole derivatives | HOFFMANN-LA ROCHE, INC. | 2009-01-08 | — | — | US | disclosed |
| WO-2009003861-A1 | IMIDAZOLE DERIVATIVES AS CCR2 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009003861-A1 | IMIDAZOLE DERIVATIVES AS CCR2 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012063-A1 | Novel imidazole derivatives | CCR2, CCR1, CCR3 | MCHR1 161/4885L3MBTL3 3062/4885L3MBTL1 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.